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Abstract
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive
sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1
(NF1) cancer predisposition syndrome. Despite aggressive multimodality therapy,
outcomes are dismal and most patients die within 5 years of diagnosis. Prior genomic
studies in our laboratory identified tyrosine kinase 2 (TYK2) as a frequently mutated
gene in MPNST. Herein, we explored the function of TYK2 in MPNST pathogenesis.
Methods: Immunohistochemistry was utilized to examine expression of TYK2 in
MPNSTs and other sarcomas. To establish a role for TYK2 in MPNST pathogenesis,
murine and human TYK2 knockdown and knockout cells were established using
shRNA and CRISPR/Cas9 systems, respectively.
Results: We have demonstrated that TYK2 was highly expressed in the majority of
human MPNSTs examined. Additionally, we demonstrated that knockdown of Tyk2/
TYK2 in murine and human MPNST cells significantly increased cell death in vitro.
These effects were accompanied by a decrease in the levels of activated Stats and
Bcl‐2 as well as an increase in the levels of Cleaved Caspase‐3. In addition, Tyk2‐KD
cells demonstrated impaired growth in subcutaneous and metastasis models in vivo.
Conclusion: Taken together, these data illustrate the importance of TYK2 in MPNST
pathogenesis and suggest that the TYK2 pathway may be a potential therapeutic target for these deadly cancers.
KEYWORDS
cancer, MPNST, sarcoma, TYK2

IN TRO D U C T ION

Malignant peripheral nerve sheath tumors are aggressive
sarcomas that account for approximately 5% of all soft tissue sarcomas. Approximately, 50% of these tumors occur

in patients with the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome, while the other half occur
sporadically or as a secondary complication of radiation
therapy.1,2 In the setting of NF1, MPNSTs arise from
malignant transformation of a benign precursor lesion, a
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plexiform neurofibroma.3 Initial treatment for MPNSTs
typically involves surgery and radiation with or without
chemotherapy.4 However, despite aggressive therapy, the
recurrence rate is high and the vast majority of people
with these cancers will die within 5 years of diagnosis.5-8
Treatment for metastatic disease is limited to cytotoxic
chemotherapy and clinical trials evaluating experimental therapies. As such, there is a pressing need to identify
novel therapeutic targets.
Prior work from our laboratory identified TYK2 as a
gene mutated and frequently overexpressed in a subset of
MPNSTs.9 Tyrosine kinase 2 (TYK2) is a member of the
Janus kinase (JAK family),10 which includes three other members, JAK1‐3. These proteins are non‐receptor tyrosine kinases that are activated by auto or trans‐phosphorylation after
a cytokine binds to its respective receptor.11,12 Subsequently,
JAKs activate signal transducers and activators of transcription proteins (STATs) which form homo‐/hetero dimers and
then following phosphorylation, translocate into the nucleus
to induce the transcription of target genes.13,14 STAT protein
family members have been shown to regulate oncogenic signaling in many tumor types often through the expression of
downstream target genes such as cyclin D, Bcl‐2, and Bcl‐x,
which regulate cell proliferation15,16 and apoptosis17 of tumor
cells. Herein, we have explored the role of TYK2 in MPNST
pathogenesis. First, we have shown that TYK2 is expressed
in over 60% of human MPNSTs. Second, knockdown of the
gene in murine and human MPNST cells led to decreased
phosphorylation of STAT proteins, decreased levels of Bcl2,
and increased cell death in vitro. Finally, we showed that
knockdown of the gene led to decreased tumor burden in
a primary and metastatic xenograft model. Taken together,
these data suggest that TYK2 is a potential therapeutic target
for MPNSTs.

2
2.1

|

|

M ETHODS

|

Cell culture

Murine MPNST tumor lines expressing GFP‐Luciferase established previously in our laboratory from C57BL6/J Nf1±;Trp53±
(NPcis),18 and human MPNST 724 cell lines obtained from
Jonathan Fletcher (Dana Farber Cancer Institute) were used for
all in vitro and in vivo experiments. Cells were cultured in high‐
glucose DMEM (Gibco Life Technologies, Grand Island, NY,
USA), with 10% FBS (Gibco Life Technologies, Grand Island,
NY, USA) and penicillin‐streptomycin (200 µg/mL).
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Lentiviruses

Lentiviral Tyk2 shRNA (TRCN0000236001, TRCN000023
6003, TRC0000361657, MilliporeSigma, St. Louis, MO) or control LacZ shRNA (McDonnell Genome Institute, Washington
University) containing pLKO.1‐puro plasmids were utilized for
in vitro and in vivo murine MPNST cell experiments. Each construct was co‐transfected into HEK293T cells with the packaging plasmid pMDLg, pCMVg, and pREV using Mirus reagent
(MilliporeSigma) to generate virus. After a 24‐hour infection,
JW23.3 murine MPNST cells were subjected to selection media
containing 2 µg/mL puromycin.
Three lentiviral shTyk2 constructs were screened and used
in vitro. The two constructs with the best knockdown were
chosen for in vivo experiments.

2.3 | CRISPR‐Cas9‐mediated TYK2
knockout in MPNST 724 cells
We designed the sgRNA using the websitehttp://tools.genome-engineering.org.19

gRNA #1‐1 CACCG GGCCCCACCTGGTAGGCATT

AAAC AATGCCTACCAGGTGGGGCC C

gRNA #1‐2 CACCG GCCATGGACAAGTGGGGGTT

AAAC AACCCCCACTTGTCCATGGC C

gRNA #2‐1 CACCG GCCCCACCTGGTAGGCATTC

AAAC GAATGCCTACCAGGTGGGGC C

gRNA #2‐2 CACCG GCCATGGACAAGTGGGGGTT

AAAC AACCCCCACTTGTCCATGGC C

gRNA #3‐1 CACCG GGAGACCTGGCTCATGAGGC

AAAC GCCTCATGAGCCAGGTCTCC C

gRNA #3‐2 CACCG GTGCATGGCGTCTGTGTGCG

AAAC CGCACACAGACGCCATGCAC C

gRNA #4‐1 CACCG ACTCAGCTTGATGAAGGGGC

AAAC GCCCCTTCATCAAGCTGAGT C

gRNA #4‐2 CACCG GGGCCTGGGCGCCCTCTCCA

AAAC TGGAGAGGGCGCCCAGGCCC C

gRNA #5‐1 CACCG CACCACCATCTTCCAAGCCA

AAAC TGGCTTGGAAGATGGTGGTG C

gRNA #5‐2 CACCG GGCCAGCGCCCTCAGCTACC

AAAC GGTAGCTGAGGGCGCTGGCC C

gRNA #6‐1 CACCG GCACACGCTGAACACTGAAG

AAAC CTTCAGTGTTCAGCGTGTGC C

gRNA #6‐2 CACCG GCAGCCCTGCCTGGGAGGAC

AAAC GTCCTCCCAGGCAGGGCTGC C

We constructed the pSpCas9n(BB)‐2A‐Puro (PX462)‐
TYK2 plasmid by inserting the sgRNA into the plasmid.
MPNST 724 cells (1 × 105 cell/well) were transfected
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(Lipofectamine, Invitrogen, USA) with the paired plasmid
with or without sgRNA. Cells were then puromycin selected for 72 hours. Two clones with the best knockout as
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demonstrated by western blot were chosen for analysis (#5
2 and #6 4 lines). One control clone was selected for further
study as well (Control 8).

2.4

|

Western blot analysis

Cells were lysed in 1× Cell Lysis Buffer (Cell Signaling
Technology, Danvers, MA). Protein content was quantified
using the BCA kit (ThermoFisher Scientific, USA). Primary
antibody incubations were performed at 4°C overnight
(phospho‐STAT1(SC‐8394), phospho‐STAT3(SC‐8001‐R),
STAT1(SC‐464), STAT3(SC‐23151), and Bcl2(SC‐7382) at
1:500, Santa Cruz Biotechnology, Dallas, Texas, USA; TYK2
(720124), GAPDH(AM4300), ThermoFisher Scientific, USA,
Caspase3(9662) and Cleaved Caspase‐3(9661) at 1:1000;
Cell Signaling Technology) diluted in 5% BSA TBS‐T.
Secondary antibodies used included goat anti‐rabbit or goat
anti‐mouse (Cell Signaling Technology) peroxidase‐conjugated antibodies (at 1:10000 dilution in 5% BSA TBS‐T). The
protein levels were calculated by measuring the peak densitometric area (Image‐J). Each western blot analysis was repeated
in triplicate. Phosphorylated and un‐phosphorylated proteins
were run and detected on the same blot after stripping.

2.5

|

mRNA quantification

RNA was isolated using the TRIzol method (ThermoFisher
Scientific, USA), then quantitated with the Nanodrop 2000
(ThermoFisher Scientific, USA). Reverse transcription reactions were performed with Superscript III (ThermoFisher
Scientific, USA) according to the manufacturer's protocols.
Quantitative PCR was performed in a CFX96 Touch™ Real‐
Time PCR Detection System (Bio‐Rad, USA) using the
SYBR® Green based qPCR kit (MilliporeSigma, St. Louis
MO, USA). Primers used included:

murine Tyk2

Forward 5′‐GTGACTCTAACCAG
AGTCCCCATA‐3′,
Reverse 5′‐CTGACCTTGGTACTT
CTCCTGTG‐3′,

human TYK2

Forward 5′‐GACAGTCCATGAGA
AGTACCAAGG‐3′,
Reverse 5′‐CTCTAGACAGGAGT
AAGGCACAC‐3′,

murine Gapdh

Forward 5′‐TCAACAGCAACTCC
CACTCTTCCA‐3′,
Reverse 5′‐ACCCTGTTGCTGTA
GCCGTATTCA‐3′,

human GAPDH

These were synthesized by IDT (Integrated DNA
Technologies, San Diego, CA). Relative gene expression
was determined using CFX ManagerTM Software version
3.1 (Bio‐Rad, USA) by CFX96 TouchTM and CFX96 Touch
Deep wellTM Real‐Time PCR Detection Systems; ms‐Gapdh
and hu‐GAPDH gene were used as reference genes for expression analysis.
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Cell proliferation and cell death assays

Control shLacZ JW23.3, shTyk2 #1 JW23.3, shTyk2 #2
JW23.3, and shTyk2 #3 JW23.3, were cultured in standard conditions with 2 µg/mL puromycin, then plated at 5000 cells/well
in 96‐well plates. For proliferation assays, cells were plated
in phenol‐red free DMEM with 10% FBS. Cells were imaged
every hour for 48 hours using the IncuCyte FLR imaging system (Essen Bioscience, Ann Arbor, MI, USA) and analyzed
for quantitation using IncuCyte ZOOM Analysis Software
(Essen Bioscience, Ann Arbor, MI) Phase images were used
to determine percent confluence and subsequent wells were
normalized to initial confluence. For cell death assays, 50nM
TOTOTM‐3 iodide (ThermoFisher Scientific, USA) was added
to the phenol‐red free media with reduced serum as a stress
(5% FBS). Cells were imaged every hour for 48 hours using the
IncuCyte FLR imaging system (Essen Bioscience, Ann Arbor,
MI). For quantification of cell death, the TOTOTM‐3 iodide fluorescence was normalized to the confluency factor calculated
from the phase of each respective well.

2.7

|

Tumor cell injections

|

Bioluminescence imaging (BLI)

For the subcutaneous model, a total of 2 × 106 shLacZ
JW23.3, shTyk2 #2 JW23.3, or shTyk2 #3 JW23.3, tumor
cells were injected into the dorsal surface of 5‐week‐old
C57BL/6 ALBINO mice (Charles River Labs). Tumor volumes were measured weekly for the first 2 weeks and then
every other day for the final week. For the left ventricular
metastatic model, a total of 1 × 105 shLacZ JW23.3, shTyk2
#2 JW23.3, or shTyk2 #3 JW23.3, tumor cells were injected
into the left ventricle of 5‐week‐old C57BL/6 ALBINO mice
(Charles River Labs). These mice were followed by bioluminescence imaging (BLI) with weekly weights. (n = 5 mice
per group). These experiments were all repeated independently and similar results were obtained. The Institutional
Animal Care and Use Committee of Washington University
has reviewed and approved our protocol for experiments utilizing animals. All animals are treated in compliance with
IACUC policies.

Forward 5′‐TGTTGCCATCAATG
ACCCCTT‐3′,

2.8

Reverse 5′‐CTCCACGACGTACT
CAGCG‐3′.

BLI was performed on an IVIS 50 or IVIS Lumina
(PerkinElmer; Living Image 4.3 or 3.2, 1 sec–5 minutes
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exposures, binning 2, 4, or 8; FOV 12 cm, f/stop1, open
filter). In vivo bioluminescence was measured weekly post
tumor cell injection following i.p. injection of D‐luciferin
(150 mg/kg; Gold Biotechnology, Inc). Total photon flux
(photons/second) was measured from fixed regions of interest over the entire mouse using Living Image 2.6.

2.9 | Statistical analysis for in vivo and
in vitro studies
In vivo tumor growth data GraphPad Prism Version 6 was
used to perform a two‐way ANOVA analysis to determine
statistical significance. Kaplan‐Meier analysis was used to
determine statistical significance for overall survival. For all
other in vivo and in vitro other experiments GraphPad Prism
Version 6 was used to perform two‐tailed t‐tests to determine
statistical significance.
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Human tissue acquisition

Unstained slides were obtained from cases from individuals diagnosed with MPNSTs and treated at Washington
University/St. Louis Children's Hospital NF Clinical Program
(St. Louis, MO) under active Human Studies Protocols approved by the Institutional Review Boards in accordance
with the 1964 Helsinki Declaration and its later amendments
or comparable ethical standards. All human tumor samples
were collected under an IRB approved protocol 201203042
and patients were appropriately consented.

2.11
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Immunohistochemistry

Immunohistochemical staining was performed using a rabbit
polyclonal antibody to TYK2 antibody at 1:1000 (ab39550;
Abcam, Cambridge, Mass), Cleaved Caspase‐3 at 1:500
(Cell Signaling Technology) with citrate antigen retrieval on
whole tissue sections from the most representative areas of the
tumor, as well as from normal peripheral nerve. Breast carcinoma was used as a positive control for TYK2 staining. Images
were acquired with the 40X objective using the Olympus DP70
Microscope Digital Camera and DP70‐BSW software. For
TYK2 staining, tumors with strong immunostaining in >80% of
the cells were scored as positive. Tumors with strong to moderate staining in 25%‐80% of cells were called moderate. Tumors
with weak staining in <25% of cells or no immunostaining were
deemed negative. No tumors called negative demonstrated any
areas of moderate to strong staining.

2.12

|

Clinical data statistical analysis

Two‐way ANOVA analyses were performed to estimate the
difference of tumor growth rates over time between Tyk2

|
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knockdown and control groups. The t‐tests were used to compare continuous variables between groups for In vitro experiments. The association between TYK2 protein expression and
H3K27 me status was assessed by Fisher's Exact Test. Patient
characteristics were compared between TYK2 normal and aberrant patients using χ2 test or Fisher exact test for categorical
variables while non‐parametric Wilcoxon rank sum test was
used for continuous variables. Kaplan‐Meier survival curves
were generated for overall survival by TYK2 protein expression groups in MPNST. Patients were censored by date of death
(Social Security Death Index, expiration note in chart or obituary) or date of last follow‐up. Overall survival is defined as date
from diagnosis to date of death by any cause. The survival difference between groups was compared using the log‐rank test.
Raw hazard ratios (HR) and 95% CI were estimated from univariate Cox model. All tests were two‐sided and P‐value ≤0.05
is considered statistically significant. Statistical analyses were
performed with GraphPad Prism Version 6 and SAS (version
9.4; SAS Institute, Cary, NC).

3

|

RESULTS

3.1 | TYK2 is expressed in the majority of
MPNSTs
We first set out to examine TYK2 expression in a set
of MPNSTs and other sarcomas in order to determine if
TYK2 expression could serve as a diagnostic biomarker
for MPNSTs. We performed IHC on full tissue sections
from 30 MPNSTs, 18 plexiform neurofibromas, 5 fibrosarcomas, 9 synovial sarcomas, 13 undifferentiated pleomorphic sarcomas, and 13 leiomyosarcomas. As can be
seen in Figure 1, strong staining was observed in 63% of
MPNSTs as well as 38%‐89% of other sarcomas, depending on the histologic subtype, but only 11% of benign
plexiform neurofibromas. Table 1 depicts the clinical data
associated with the MPNSTs in this study. A Fischer Exact
Test was performed for each clinical parameter to see if
there was any correlation between TYK2 expression. In
this small sample size, no statistically significant correlation was observed. The polycomb repressive complex 2
(PRC2)/polycomb repressive complex 2 subunit (SUZ12)
has recently been shown to play an important role in
MPNST pathogenesis.20,21 Given that PRC2 loss occurs
in 60%‐70% of MPNSTs and affects transcriptional regulation, we sought to determine whether there was a correlation between PRC2 loss and TYK2 expression, which
could suggest a link between these events. As a surrogate
for PRC2/SUZ12 loss, we performed immunohistochemistry to examine H3K27 me3, a known downstream target
of SUZ12. However, there was no correlation between
these events in this cohort as determined by a Fischer

5236
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F I G U R E 1 Tyrosine kinase 2 (TYK2)
protein expression in malignant peripheral
nerve sheath tumors (MPNSTs) and other
sarcomas. TYK2 immunoreactivity was
observed NF1‐associated and sporadic
MPNSTs as well as other sarcomas.
(A) Representative images of positive
and negative staining for Plexiform
Neurofibromas, NF1‐associated MPNSTs,
sporadic MPNSTs, and Undifferentiated
Pleomorphic Sarcoma (UPS), and
fibrosarcoma. (B) Quantification of number
of positive and negative cases observed for
each type of tumor

TYK2

A

Strong/Moderate

Weak/Negative

Plexiform Neurofibroma

MPNST

Sporadic MPNST

Fibrosarcoma

B
Tumor Type Strong/Moderate
Plexiform neurofibroma

2/18 (11%)

MPNST 19/30 (63%)

Weak/Negative
16/18
11/30

Synovial sarcoma 8/9 (89%)

1/9

Fibrosarcoma 3/5 (60%)

2/5

7/13 (54%)

6/13

Leiomyosarcoma 5/13 (38%)

8/13

Undifferentiated pleomorphic sarcoma(UPS)

Exact Test. Nonetheless, these data do suggest that TYK2
protein overexpression is prevalent in malignant tumors
and could be targetable in MPNSTs as well as other sarcomas. Given that TYK2 is expressed at high levels in the
majority of MPNSTs, we went on to look at the functional
role in this subset of sarcomas.

3.2 | Loss of TYK2 leads to increased cell
death in vitro
To explore the function of Tyk2 in vitro, we utilized JW23.3
Nf1/Tp53‐ mutant NPcis murine MPNST cells engineered
to express firefly luciferase. Following Tyk2 shRNA‐mediated knockdown, there was reduced expression of Tyk2
by western blot compared to control shLacZ virus infection
(Figure 2A), as well as decreased expression at an mRNA
level (Figure 2B). Reduced Tyk2 expression was associated with decreased cell confluence over time (Figure 2C,

Supplemental Figure S1A) as well as increased cell death
as assessed by increased incorporation of TOTOTM‐3 iodide, a fluorescent dye binding to cell‐free DNA (Figure
2D, Supplemental Figure S1B) compared to control cells.
To ensure that these data were not an artifact of a single
cell line, we next used the CRSIPR/Cas9 system to knockout
TYK2 in human MPNST 724 cells and demonstrated similar
findings (Figure 2E‐H, Supplemental Figure S1C and D). To
explore potential downstream targets by which TYK2 could
be exerting its effects on cell death in MPNSTs, we first examined phosphorylation status of several downstream STAT
proteins, as these are known targets for Tyk2.16,17 As can
be seen in Figure 3, upon knockdown of Tyk2 (Figure 3A
and B) there was a significant reduction in levels of phospho‐STAT1 and phospho‐STAT3 in both murine and human
cell lines (Figure 3C‐F). Additionally, there was a decrease
in levels of the anti‐apoptotic protein, Bcl‐2 (Figure 3G
and H), another protein shown to be regulated by TYK2 in
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TABLE 1

MPNST patient

Clinical characteristics of

TYK2 positive
(N = 18)

TYK2 Negative
(N = 11)

Total
(N = 29)

Male

10 (56)

4 (36)

14 (48)

Female

8 (44)

7 (64)

15 (52)

Median

39

47

42

Range

22‐60

18‐79

18‐79

Characteristic
Sex, n (%)

0.4486

NF1

8 (44)

3 (27)

11 (38)

Sporadic

10 (56)

8 (73)

18 (62)

Grade, n (%)

n/a

High

18 (100)

11 (100)

29 (100)

Low

0 (0)

0 (0)

0 (0)

Stage at diagnosis, n (%)

1.0

IV

3 (17)

1 (9)

4 (14)

Other

15 (83)

10 (91)

25 (86)

Extremity

2 (11)

5 (45)

7 (28)

Other

15 (83)

6 (55)

21 (72)

Site of tumor, n (%)

0.3312

H3K27 Trimethylation
staining, n (%)

0.4328

Positive

11 (61)

4 (36)

15 (52)

Negative

7 (39)

6 (54)

13 (45)

We next chose shTyk2 #2 and shTyk2 #3 to use to determine
the effects of Tyk2 knockdown in vivo using the JW23.3
Nf1/Tp53‐mutant NPcis murine MPNST cells. These lines
were chosen as they produced the greatest and most consistent knockdown of Tyk2. In a subcutaneous model of
tumor growth, we observed decreased tumor volume over
time in the setting of Tyk2 knockdown (Figure 4A and B).
Additionally, tumor sections from these mice demonstrated
increased numbers of Cleaved Caspase‐3 positive cells
(Figure 4C and 4D), demonstrating that at least a subset
of cells are going through apoptosis. Furthermore, in a left
ventricular tumor injection model of tumor dissemination
and metastasis, we observed decreased tumor burden over
time in mice injected with Tyk2‐deficent cells compared to
mice injected with control cells (Figure 4E and 4F). This
was associated with decreased weight loss (Supplemental
Figure S2A) and increased overall survival (Supplemental
Figure S2B).

P‐value

0.3419

NF Status, n (%)

3.3 | Loss of TYK2 leads to decreased
tumor burden in vivo

5237

0.4497

Age at diagnosis, y

other models.16 This was associated with increased levels of
Cleaved Caspase‐3 (Figure 3I and J).

|
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|

DISCUSSION

MPNSTs are aggressive sarcomas with limited treatment options and a dismal overall survival. As such, better therapies
are desperately needed for these tumors. Prior work from our
laboratory identified potential activating mutations in TYK2
in one‐third of MPNSTs examined. TYK2, a member of the
Janus Kinase family of proteins has been shown to play a role
in immune surveillance and host response in the setting of
infection, autoimmune disorders, and malignancy.22-25 More
recent cancer genomic studies have identified activating
mutations in TYK2 within cancer cells, implicating a cell intrinsic role for TYK2 in promoting cancer progression.9,25-27
Based on these genomic studies, we have begun to explore
the role of TYK2 in MPNST pathogenesis. The current study
raises several important points. First, we have demonstrated
the TYK2 is present in the majority of MPNSTs. In this cohort, we performed an analysis to see if there was any correlation between TYK2 expression and overall survival or any
other clinical parameter. Unfortunately, we did not see any
statistically significant associations in this set. Future work
is aimed obtaining a larger sample set through collaboration
with several other NF centers. Nonetheless, the strong staining in the majority of MPNSTs suggests that TYK2 could be

|
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F I G U R E 2 Loss of Tyk2/TYK2 in
JW23.3 murine MPNST and MPNST 724
cells leads to increased cell death. shTyk2‐
infected JW23.3 cell lines and control
shLacZ: (A) Western blot densitometry
analysis measuring TYK2 protein. (B)
Relative Expression of Tyk2 mRNA
compared to Gapdh. (C) An Incucyte cell
proliferation assay measuring confluence
over time. (D) An Incucyte death assay
measuring TOTOTM-3 iodide fluorescence
as an indicator of death over time. TYK2
knockout MPNST 724 cells and scramble
control: (E) Western blot densitometry
analysis of TYK2 protein. (F) Relative
Expression of TYK2 mRNA compared to
GAPDH. (G) An Incucyte cell proliferation
assay measuring confluence over time.
(H) An Incucyte death assay measuring
TOTOTM-3 iodide fluorescence as an
indicator of death over time. (*P < 0.05,
**P < 0.01, ***P < 0.001)
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a therapeutic target for a large proportion of these tumors.
While, we had initially hoped that expression of TYK2 could
serve as a potential biomarker distinguishing MPNSTs from
other soft tissue sarcomas, we observed high expression in
38%‐89% of other sarcomas as well. As such, TYK2 expression is unlikely to serve as a diagnostic biomarker for
MPNSTs, but these data do suggest that TYK2 could be a
therapeutic target in other sarcoma subtypes as well. Future
work is aimed at evaluating this possibility.
Second, we have demonstrated that decreased expression of TYK2 in both human and mouse MPNST cells leads
to decreased cell survival, decreased activation of STAT1
and 3, and decreased levels of Bcl2 in vitro. Interestingly,

Time (h)

STAT3 has been previously implicated in MPNST pathogenesis.28 Taken together, these data suggest that the TYK2
pathway could serve as a therapeutic target in MPNSTs.
Future work is aimed at dissecting the upstream components in this pathway and identifying other downstream targets that could be involved in controlling TYK2‐dependent
cell survival. Third, we demonstrate that reduced levels of
Tyk2 leads to decreased tumor growth in subcutaneous and
left ventricular models of tumor inoculation in a murine
MPNST. Interestingly, while there were far more Cleaved
Caspase‐3 positive cells in the Tyk2 knockdown tumors
compared to control, there were still a large number of
cells that were not Cleaved Caspase‐3 positive. Despite this
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F I G U R E 3 Knockdown of
Tyk2/TYK2 in JW23.3 murine MPNST
and MPNST 724 cells affects expression
of downstream targets. Western blot
densitometry analysis on downstream
targets of Tyk2/TYK2. Murine JW23.3 cell
lines are depicted in blue/green, human
MPNST 724 cell line are depicted in
black/orange. (A and B) levels of TYK2
normalized to GAPDH (C and D) levels
of p‐STAT1 normalized to total STAT1.
(E and F) levels of p‐STAT3 normalized
to total STAT3. (G and H) levels of Bcl‐2
normalized to GAPDH (I and J) levels
of Cleaved Caspase-3 normalized to
Caspase 3 levels. (*P < 0.05, **P < 0.01,
***P < 0.001) All experiments were done
in triplicate. Representative blots are shown
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F I G U R E 4 shRNA‐mediated
knockdown of Tyk2 in JW23.3 murine
MPNST cells leads to decreased tumor
growth in vivo. (A) Dissected tumors from
subcutaneous injection of shTyk2‐infected
JW23.3 cell lines and control shLacZ. (B)
Quantification of subcutaneous tumor
volume over time. (C) Quantification of the
number of Cleaved Caspase-3 positive cells
from immunohistochemistry of harvested
subcutaneous tumors of shTyk2‐infected
JW23.3 cell lines and control shLacZ.
(D) Representative images of Cleaved
Caspase-3 immunohistochemistry. (E)
Tumor burden over time as measured
by photon flux in mice injected
intraventricularly. (F) Representative
images of mice following intraventricular
injection. (n = 5 for all groups; *P < 0.05,
**P < 0.01, ***P < 0.001)
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fact, there was a very significant decrease in tumor burden,
suggesting that there may be other cell death mechanisms
at play in addition to apoptotic cell death. Nonetheless,
the mice injected with Tyk2‐deficient cells exhibited less
weight loss and had an increased overall survival, further
supporting targeting this pathway in MPNSTs. Future studies will be aimed at better understanding the mechanisms
at play in vivo. As we move forward with evaluating this
pathway as a viable therapeutic target, another important
aspect of TYK2 signaling that cannot be ignored is that
TYK2 does not act alone, but is rather in a receptor complex in which either JAK1 or JAK2 is also involved. Thus,
drug development strategies will benefit from understanding which of the other JAK family members are important
in MPNST biology. Future work will be aimed at identifying the most effective inhibitor from in vitro studies and
then evaluating the in vivo efficacy of the most promising

TYK2 inhibitors to test as a single agent and in combination therapies.
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